4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
10.76
-0.03 (-0.28%)
May 12, 2026, 9:44 AM EDT - Market open
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $3.05M in the quarter ending March 31, 2026, with 21,664.29% growth. This brings the company's revenue in the last twelve months to $88.24M, up 383,560.87% year-over-year. In the year 2025, 4D Molecular Therapeutics had annual revenue of $85.21M with 230,194.59% growth.
Revenue (ttm)
$88.24M
Revenue Growth
+383,560.87%
P/S Ratio
6.39
Revenue / Employee
$450,214
Employees
196
Market Cap
562.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 85.21M | 85.17M | 230,194.59% |
| Dec 31, 2024 | 37.00K | -20.69M | -99.82% |
| Dec 31, 2023 | 20.72M | 17.59M | 562.29% |
| Dec 31, 2022 | 3.13M | -14.91M | -82.65% |
| Dec 31, 2021 | 18.04M | 4.43M | 32.52% |
| Dec 31, 2020 | 13.61M | 6.63M | 94.85% |
| Dec 31, 2019 | 6.99M | -7.14M | -50.56% |
| Dec 31, 2018 | 14.13M | 8.34M | 144.04% |
| Dec 31, 2017 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| CorMedix | 311.71M |
| Ginkgo Bioworks Holdings | 151.40M |
| Prime Medicine | 4.03M |
| Shattuck Labs | 1.00M |
| ProKidney | 893.00K |
| Avalo Therapeutics | 59.00K |
| Altimmune | 41.00K |
FDMT News
- 4 days ago - 4D Molecular price target lowered to $33 from $38 at Goldman Sachs - TheFly
- 4 days ago - 4D Molecular files $400M mixed securities shelf - TheFly
- 4 days ago - 4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 8 days ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 24 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - 4D Molecular price target lowered to $23 from $45 at Evercore ISI - TheFly
- 6 weeks ago - 4D Molecular assumed with a Buy at Jefferies - TheFly
- 7 weeks ago - 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire